BIODESIX INC (BDSX)
US09075X1081 - Common Stock
We assign a fundamental rating of 2 out of 10 to BDSX. BDSX was compared to 117 industry peers in the Health Care Providers & Services industry. BDSX may be in some trouble as it scores bad on both profitability and health. BDSX is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year BDSX has reported negative net income.
In the past year BDSX has reported a negative cash flow from operations.
In the past 5 years BDSX always reported negative net income.
In the past 5 years BDSX always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -52.62%, BDSX is not doing good in the industry: 87.93% of the companies in the same industry are doing better.
BDSX's Return On Equity of -1138.62% is on the low side compared to the rest of the industry. BDSX is outperformed by 83.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -52.62% | ||
| ROE | -1138.62% | ||
| ROIC | N/A |
ROA(3y)-59.93%
ROA(5y)-55.91%
ROE(3y)-558.46%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of BDSX (73.49%) is better than 92.24% of its industry peers.
In the last couple of years the Gross Margin of BDSX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for BDSX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 73.49% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.43%
GM growth 5Y-1.3%
2. Health
2.1 Basic Checks
BDSX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BDSX has more shares outstanding
Compared to 5 years ago, BDSX has more shares outstanding
BDSX has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -5.84, we must say that BDSX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -5.84, BDSX is not doing good in the industry: 85.34% of the companies in the same industry are doing better.
A Debt/Equity ratio of 7.69 is on the high side and indicates that BDSX has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 7.69, BDSX is doing worse than 81.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 7.69 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.84 |
ROIC/WACCN/A
WACC9.54%
2.3 Liquidity
A Current Ratio of 1.19 indicates that BDSX should not have too much problems paying its short term obligations.
The Current ratio of BDSX (1.19) is comparable to the rest of the industry.
A Quick Ratio of 1.19 indicates that BDSX should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.19, BDSX is in line with its industry, outperforming 46.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.19 | ||
| Quick Ratio | 1.19 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 59.12% over the past year.
Looking at the last year, BDSX shows a very strong growth in Revenue. The Revenue has grown by 28.44%.
Measured over the past years, BDSX shows a quite strong growth in Revenue. The Revenue has been growing by 19.16% on average per year.
EPS 1Y (TTM)59.12%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q71.43%
Revenue 1Y (TTM)28.44%
Revenue growth 3Y2.52%
Revenue growth 5Y19.16%
Revenue growth Q2Q52.63%
3.2 Future
Based on estimates for the next years, BDSX will show a very strong growth in Earnings Per Share. The EPS will grow by 20.48% on average per year.
BDSX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 25.65% yearly.
EPS Next Y33.31%
EPS Next 2Y22.07%
EPS Next 3Y20.48%
EPS Next 5YN/A
Revenue Next Year30.21%
Revenue Next 2Y25.59%
Revenue Next 3Y25.65%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
BDSX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BDSX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as BDSX's earnings are expected to grow with 20.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.07%
EPS Next 3Y20.48%
5. Dividend
5.1 Amount
No dividends for BDSX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIODESIX INC
NASDAQ:BDSX (4/26/2024, 7:00:00 PM)
1.235
-0.02 (-1.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap140.33M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -52.62% | ||
| ROE | -1138.62% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 73.49% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 7.69 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.19 | ||
| Quick Ratio | 1.19 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)59.12%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y33.31%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)28.44%
Revenue growth 3Y2.52%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y